SureTrader SureTrader SureTrader
Home > Boards > US OTC > Miscellaneous >

Rich Pharmaceuticals Inc. (RCHA)

Add RCHA Price Alert      Hide Sticky   Hide Intro
Moderator: Axeman, otclad
Search This Board:
Last Post: 1/13/2017 8:43:16 AM - Followers: 172 - Board type: Free - Posts Today: 0

RCHA Patent for Treatment of Hodgkin’s Lymphoma

Under terms of the agreement, Rich Pharmaceuticals, Inc. will obtain complete ownership and all interest in the indication, patents and intellectual property related to treatment of Hodgkin’s Lymphoma,
RCHA Recent News

Rich Pharmaceuticals Announces Additional Submission To The U.S. Food and Drug Administration (FDA)

BEVERLY HILLS, Calif., Nov. 23, 2015 /PRNewswire/ -- Rich Pharmaceuticals, Inc. (OTCPK: RCHA) ("Rich"), with the advice and guidance of Theradex Systems, Inc.,

Rich Pharmaceuticals Announces Completion of the Manufacture of RP-323 Study Drug in Connection with Obtaining FDA's Final Approval of The Investigational New Drug
(IND) Application For The Treatment of Acute Myelocytic Leukemia

BEVERLY HILLS, Calif., Feb. 4, 2015 /PRNewswire/ -- Rich Pharmaceuticals, Inc. (RCHA) ("Rich" or the "Company"), a clinical-stage biotechnology company focused on developing innovative therapies in oncology, announced today that it has competed a GMP clinical batch of RP-323 study drug that was manufactured at the state-of-the-art Wuxi Apptec Biopharmaceutical's facility based in Shanghai, China.  This new batch of RP-323 represents a new second-generation compound with improved product usability and stability.  Rich Pharmaceuticals developed the new formulation and all regulatory required testing methods in 2014 and transferred the proprietary technology successfully to Wuxi Apptec for the GMP production of RP-323.  Currently, the new study drug is in the final examination stage at Wuxi Apptec and is expected to be shipped to clinical sites starting mid-February 2015 for the upcoming planned clinical trials.   
Rich Pharmaceuticals submitted its Investigational New Drug (IND) Application for a Phase 2 multi-center study to evaluate the safety and efficacy of RP-323 in patients with AML and MDS in October 2014. 
In connection with the IND, Rich Pharmaceuticals was required to manufacture sufficient quantities of RP-323 under GMP.
"We believe RP-323 has best-in-class potential and holds significant promise for patients suffering from AML and MDS," said Ben Chang, Rich Pharmaceuticals' Chief Executive Officer. 
Mr. Chang further stated, "We are especially excited to have a partner in the manufacture of RP-323 of the high caliber of Wuxi Apptec. 
We expect to pursue the approval of the IND promptly and to be in clinical studies in the very near term."
About Rich Pharmaceuticals:
Rich Pharmaceuticals, Inc. (RCHA) is a biopharmaceutical company developing a treatment for Acute Myelocytic Leukemia (AML)/white blood cell elevation, Hodgkin's Lymphoma and other blood related diseases. 
Rich Pharmaceuticals' goal is to extend refractory patients life expectancy and increase quality of life. 
Rich Pharmaceuticals' primary development stage product candidate, RP-323, is being designed to treat blood and cancer related diseases through non-evasive outpatient facilities. 

Find out more at
WuXi PharmaTech, Inc. trades on the NYSE in the area of $40.00 per share under the ticker of WX with a $2.8 Billion Market Cap:

Below is the indicated Product Pipeline for RCHA:

Here is a key piece from the news as to how it applies:
"We believe RP-323 has best-in-class potential and holds significant promise for patients suffering from AML and MDS," said Ben Chang, Rich Pharmaceuticals' Chief Executive Officer.  Mr. Chang further stated, "We are especially excited to have a partner in the manufacture of RP-323 of the high caliber of Wuxi Apptec.  We expect to pursue the approval of the IND promptly and to be in clinical studies in the very near term."

Courtesy of Sibware: 
RCHA RP-323:Potential Market=$1 to 2 Billion/Year US.$5 Billion Worldwide. 

Business Overview 

The Company is developing RP-323 (formerly called PD-616) for the treatment of Acute Myelogenous Leukemia (AML), and to cause elevation of white blood cells
(WBC) in patients depleted of these elements due to various conditions.

Clinical Studies in Acute Myelocytic Leukemia 

Based on the known properties of RP-323, it was first administered in a pilot study in China, either alone or in combination with standard drugs and caused temporary remission of AML in some patients’ refractory to standard therapy. Several patients recovered sufficiently with RP-323 treatment to return to their normal occupations, symptom-free. 
Interest in these findings led to a Phase I investigator-sponsored trial in 35 patients by a leading oncologist at a leading cancer hospital in New Jersey, the University of Medicine and Dentistry of New Jersey (UMDNJ). 

Market Opportunities 


It is estimated that 40,000 people in the US have AML and an additional 14,000 are diagnosed annually with a yearly death rate of over 10,000.
Based on this incidence,
the potential market for RP-323 for the treatment of AML is approximately $1 to 2 billion peak sales annually in the US and more than $5 billion worldwide.

RCHA Key DD Posts:
Key RCHA & WX:NYSE Relationship
Respectfully, again, key with the Authorized Shares



Contact Us
9595 Wilshire Boulevard, Ste. 900
Beverly Hills, CA 90045

P: 424.230.7001
F: 424.230.7003

E: [email protected]



Monthly View

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
News News Alert: Current Report Filing (8-k) 01/19/2017 11:15:16 AM
#11359  Sticky Note This is a Share Printing Scam Stock... AVOID makinezmoney 03/11/16 02:37:25 PM
#11965   RCHA IS THE MOST TOXIC PENNY STOCK AVAILABLE. SCAM onthegreen 01/13/17 08:43:16 AM
#11964   Wrong. RS will pop the price then all Axeman 01/12/17 12:44:01 PM
#11963   Ben Ceo has nothing but toxic financing. Good Axeman 01/12/17 12:40:29 PM
#11962   Bear !!! Time to pump this to get Pstats 01/12/17 10:05:06 AM
#11961   The Note bear interests at the rate of otclad 01/12/17 09:47:21 AM
#11960   LMFAO, ANOTHER 8K! BILLIONS DILUTED. AMAZED AT THE STUPIDITY onthegreen 01/11/17 07:16:02 PM
#11959   In my opinion, reverse split is 'no change' stockscheers 01/05/17 09:22:39 PM
#11958   It will happen again IMO. Toxic mess thanks Axeman 12/22/16 01:40:13 PM
#11957   i hope this guy has his resume ready vhgier 12/19/16 10:32:21 PM
#11956   YEP, CHECK THE HISTORY LOL onthegreen 12/13/16 09:06:26 PM
#11955   REVERSE SPLIT ON A "NO BID" STOCK, REALLY!!!!!!!!!!!!!!!!!!!!!! stoprun 12/13/16 05:58:02 PM
#11954   WARNED YA! LMAO NO BID - REVERSE SPLIT NEXT onthegreen 12/13/16 03:24:09 PM
#11952   This was supposed to be up out of otclad 12/09/16 02:14:01 PM
#11951   CHANG'S STILL CONVERTING BILLIONS OF SHARES HERE - SCAM onthegreen 12/06/16 10:38:42 AM
#11950   I have 2M buy order at .0001 AON. casinoo 12/01/16 10:46:18 AM
#11949   Oh you got me LOL . Both Axeman 11/30/16 03:09:59 PM
#11948   I'm just doing the same thing that you stoprun 11/30/16 02:11:29 PM
#11947   Reverse will happen again IMO. IN MY OPINION. Axeman 11/30/16 01:03:18 PM
#11946   "LINK PLEASE"!!!!!!!!!!! stoprun 11/29/16 05:35:25 PM
#11945   ANOTHER REVERSE SPLIT COMING HERE. GET OUT onthegreen 11/29/16 03:46:26 PM
#11944   That is the only price I would buy Axeman 11/29/16 11:44:52 AM
#11943   I have 3M buy order at 0.0001 AON casinoo 11/29/16 11:18:35 AM
#11942   RCHA business is to sell shares..that is the sizzle. Axeman 11/29/16 10:52:11 AM
#11941   The business is the steak behind the sizzle! stockscheers 11/23/16 11:21:07 PM
#11940   10Q = PROOF OF BEN CHANG'S SCAM. ATM MACHINE onthegreen 11/21/16 01:35:05 PM
#11939   What? Revenues? What planet are you living on? Axeman 11/18/16 09:50:08 AM
#11938   We all need to be patient right now. stockscheers 11/17/16 09:06:14 PM
#11937   I agree with your analysis but I would stockscheers 11/17/16 09:01:21 PM
#11936   This Market is a cesspool but Ben doesn't Axeman 11/16/16 06:45:10 PM
#11935   ONE (1) share traded, some people might call stoprun 11/16/16 01:24:17 PM
#11934   Your sense is way off especially with how Axeman 11/14/16 11:54:52 AM
#11933   Yes, you are indeed correct! My sense is stockscheers 11/13/16 09:17:59 PM
#11932   and No bid. Dead stock until Ben gets Axeman 11/10/16 01:48:20 PM
#11931   Volume really picking up here. Something must be OTC Knight 11/09/16 08:14:55 PM
#11930   Doubt it. Just more shares getting converted from 8k's. Axeman 11/09/16 04:02:48 PM
#11929   Yep. Fever pitch going on. Time to watch stockscheers 11/09/16 12:16:13 AM
#11928   I'm glad I found a few other winners. vhgier 11/04/16 09:00:27 PM
#11927   Actually toxic share dumping by the note holders. Axeman 11/04/16 04:47:47 PM
#11926   Guess we have to look at the ask stockscheers 11/03/16 11:13:47 PM
#11925   Wow no bid is coming at a much HMONNY 11/01/16 06:44:47 PM
#11924   way better ways to fund a company and vhgier 10/31/16 09:18:40 PM
#11923   LMFAO! MORE 8K's! BEN CHANG = THIEF! THIS onthegreen 10/31/16 04:54:03 PM
#11922   Okay let's just say it's been toxic deals okay? Axeman 10/28/16 03:28:40 PM
#11921   My question to you is, "How do you stoprun 10/28/16 02:07:34 PM
#11920   Look at the last 2 days Axeman 10/28/16 12:39:53 PM
#11919   Looks like Ben is doing more converting today, stoprun 10/28/16 12:28:41 PM
#11918   No big fish in this pond it has Axeman 10/27/16 10:07:08 PM
#11917   Be patient this will pay off just waiting stockscheers 10/27/16 10:06:10 PM
#11916   Converting like there's no tomorrow no-bid coming again Axeman 10/27/16 04:52:14 PM
#11915   Okie dokie good luck to us. My big Axeman 10/25/16 02:16:42 PM